Imugene Ltd (IMU) - Total Liabilities
Based on the latest financial reports, Imugene Ltd (IMU) has total liabilities worth AU$25.80 Million AUD (≈ $18.26 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Imugene Ltd cash conversion from operations to assess how effectively this company generates cash.
Imugene Ltd - Total Liabilities Trend (1993–2025)
This chart illustrates how Imugene Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Imugene Ltd (IMU) asset resilience to evaluate the company's liquid asset resilience ratio.
Imugene Ltd Competitors by Total Liabilities
The table below lists competitors of Imugene Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Perdana Gapura Prima Tbk
JK:GPRA
|
Indonesia | Rp545.11 Billion |
|
Agroton Public Ltd.
WAR:AGT
|
Poland | zł2.76 Million |
|
Richmond Vanadium Technology Ltd
AU:RVT
|
Australia | AU$1.23 Million |
|
Proteomics International Laboratories Ltd
AU:PIQ
|
Australia | AU$1.81 Million |
|
Old Market Capital Corporation
NASDAQ:OMCC
|
USA | $15.18 Million |
|
Evaxion Biotech AS
NASDAQ:EVAX
|
USA | $13.14 Million |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
USA | $40.60 Million |
|
Hitron Systems
KO:019490
|
Korea | ₩26.38 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Imugene Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IMU stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.77 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imugene Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imugene Ltd (1993–2025)
The table below shows the annual total liabilities of Imugene Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$38.56 Million ≈ $27.28 Million |
+16.33% |
| 2024-06-30 | AU$33.14 Million ≈ $23.45 Million |
+345.66% |
| 2023-06-30 | AU$7.44 Million ≈ $5.26 Million |
-16.45% |
| 2022-06-30 | AU$8.90 Million ≈ $6.30 Million |
+31.06% |
| 2021-06-30 | AU$6.79 Million ≈ $4.81 Million |
+25.80% |
| 2020-06-30 | AU$5.40 Million ≈ $3.82 Million |
+54.93% |
| 2019-06-30 | AU$3.48 Million ≈ $2.47 Million |
+142.19% |
| 2018-06-30 | AU$1.44 Million ≈ $1.02 Million |
+12.15% |
| 2017-06-30 | AU$1.28 Million ≈ $907.76K |
-23.60% |
| 2016-06-30 | AU$1.68 Million ≈ $1.19 Million |
+21.45% |
| 2015-06-30 | AU$1.38 Million ≈ $978.36K |
-27.20% |
| 2014-06-30 | AU$1.90 Million ≈ $1.34 Million |
+172.09% |
| 2013-06-30 | AU$698.03K ≈ $493.90K |
+184.94% |
| 2012-06-30 | AU$244.97K ≈ $173.33K |
-48.99% |
| 2011-06-30 | AU$480.28K ≈ $339.83K |
+56.25% |
| 2010-06-30 | AU$307.37K ≈ $217.49K |
-29.62% |
| 2009-06-30 | AU$436.72K ≈ $309.01K |
-11.48% |
| 2008-06-30 | AU$493.37K ≈ $349.09K |
-11.99% |
| 2007-06-30 | AU$560.55K ≈ $396.62K |
-30.46% |
| 2006-06-30 | AU$806.04K ≈ $570.32K |
+95.87% |
| 2005-06-30 | AU$411.52K ≈ $291.18K |
-29.57% |
| 2004-06-30 | AU$584.29K ≈ $413.43K |
-16.62% |
| 2003-06-30 | AU$700.77K ≈ $495.84K |
+1259.15% |
| 2002-06-30 | AU$51.56K ≈ $36.48K |
-98.07% |
| 2001-06-30 | AU$2.67 Million ≈ $1.89 Million |
+195.33% |
| 2000-06-30 | AU$903.09K ≈ $638.99K |
+0.57% |
| 1999-06-30 | AU$898.00K ≈ $635.39K |
-20.95% |
| 1998-06-30 | AU$1.14 Million ≈ $803.79K |
-8.46% |
| 1997-06-30 | AU$1.24 Million ≈ $878.09K |
+10.12% |
| 1996-06-30 | AU$1.13 Million ≈ $797.42K |
-13.64% |
| 1995-06-30 | AU$1.30 Million ≈ $923.37K |
+927.56% |
| 1994-06-30 | AU$127.00K ≈ $89.86K |
-78.36% |
| 1993-06-30 | AU$587.00K ≈ $415.34K |
-- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more